Effect of gamma-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo.

Trial Profile

Effect of gamma-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Semagacestat (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms IDENTITY
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Jul 2013 Primary endpoint 'Alzheimer's-Disease-Cooperative-Study-Activities-of-Daily-Living-Inventory' has not been met.
    • 25 Jul 2013 Primary endpoint 'Alzheimer's-Disease-Assessment-Scale-cognitive-subpart' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top